aminoglutethimide and hydrocortisone, but no other medication known to cause marrow failure, and all started with a normal blood count. At the time of agranulocytosis none had metastatic bone marrow disease or other evidence of recurrence of tumour, suggesting a direct toxic effect of the drug. Finally, none of the patients had had any type of drug reaction or allergy in the past.
Case reports
Case 1-A 73 year old woman presented on 12 December 1983 as an acute surgical emergency with abdominal pain 56 days after starting adjuvant treatment with aminoglutethimide. She was shocked, had a temperature of 39-8°C, and was diagnosed as suffering from intestinal perforation with peritonitis. Her white cell count, however, was 03 x 109/1 (no granulocytes) (figure) . Haemoglobin concentration and platelet count were normal and the bone marrow aspirate showed absence of myeloid precursor cells. Despite intensive resuscitation she died. Necropsy confirmed septicaemia with no evidence of metastatic breast cancer.
Case 2-On 27 August 1984 a 64 year old woman developed septicaemia with agranulocytosis (white cell count 0-5 X 109/1) while having postoperative radiotherapy. She had been receiving adjuvant aminoglutethimide for 47 days. Haemoglobin concentration was 11-2 g/dl and the platelet count 439 x 109/1 (figure). Bone White cell (----) and platelet counts (0.0---) during aminoglutethimide treatment of three patients with primary breast cancer. Arrows indicate day aminoglutethimide stopped. cells (myeloid to erythroid ratio 1:1), normal megakaryocytes, and no malignant cells. She was successfully treated with antibiotics and the white cell count recovered to >3 Ox 109/1 12 days after stopping aminoglutethimide with an associated thrombocytosis of 985 X 109/1. Three weeks after stopping aminoglutethimide bone marrow aspirate and peripheral blood cell count were normal, and four months later she remained well with a normal blood count and no evidence of recurrent carcinoma. Since 1978 this patient has been taking chlorthalidone (50 mg/day) for mild hypertension, which she continued with no adverse reaction.
Case 3-On 29 December 1982 a 67 year old woman developed agranulocytosis (white cell count 0-1 X 109/1) with a haemoglobin concentration of 9 7 g/dl and a platelet count of 272 x 109/l (figure). She had been taking adjuvant aminoglutethimide for 60 days. She was asymptomatic apart from mild monilial stomatitis. Although there was no evidence of septicaemia, she was admitted for observation and prophylaxis with antibiotics. Bone marrow aspirate was hypocellular with absent myeloid precursors, scanty erythroid precursors, and occasional megakaryocytes with no malignant cells. Nineteen days after stopping aminoglutethimide her white cell count had recovered to 6-4X 109/l with an associated thrombocytosis (534X 109/l).
Eight months later she remained well with a normal blood cell count and no evidence of recurrent carcinoma. She had also taken ferrous sulphate (200 mg/ day) and occasional metoclopramide (10 mg) and diazepam (2 mg) in the weeks before developing agranulocytosis.
Comment
These three patients developed agranulocytosis five to eight weeks after starting aminoglutethimide and hydrocortisone. None had evidence of metastases and we therefore presume that the cause of bone marrow failure was drug toxicity by aminoglutethimide. Although serious and potentially fatal, the condition is uncommon (roughly 2% of cases) and reversible on stopping treatment. The reduction in granulocytes and other precursors in the bone marrow may indicate a direct toxic effect of the drug rather than immune peripheral destruction. This is consistent with the relatively rapid recovery associated with a rebound thrombocytosis. Finally, the serial blood counts in case 2 showed a gradual decrease in white cells. Case report A 20 year old girl was admitted with an exacerbation of Crohn's disease. Owing to the severity of her condition she was treated with intravenous steroids and antibiotics, and a parenteral feeding regimen was begun through a right subclavian line. She steadily improved clinically and was beginning to tolerate oral feeding. After two weeks the subclavian line was due to be removed, but unexpectedly the nurses found her unconscious on the floor of her single room. She had obviously fallen from a bedside commode. She had probably removed the subclavian line (she was unable to recall the event, but disliked the line). The plastic introducer was still in situ th-ough the skin, with blood leaking from it. She had probably been in that position for less than five minutes.
She had signs of severe cerebral irritation, with fixed dilated pupils, extensor limb response to pain, and extreme restlessness. Her reflexes were brisk, but the plantars were downgoing. Her pulse rate was 110/minute and blood pressure 85 mm Hg systolic. Her respiratory rate was raised. Funduscopy yielded normal results, and the only other abnormal finding was a churning noise in the chest on auscultation. Air embolism was diagnosed. She was initially treated with high dose oxygen, dexamethasone, mannitol, and diazepam and was transferred to the intensive care unit.
As Initially 100% oxygen should be given with the patient in a left lateral head down position; this position prevents a large air bubble from blocking the pulmonary outflow tract and reduces the volume of air reaching the carotid arteries. In our patient the embolus was venous and the collapse was probably due to air bubbles ascending the internal jugular veins into the cerebral sinuses. An alternative explanation is that small bubbles coalesced after passing through the pulmonary circulation, or that air passed through a septal defect or an intrapulmonary atrioventricular shunt. The chuming sound heard was probably the well described millwheel murmur. Incidence of hyperkalaemia induced by indomethacin in a hospital population
Non-steroidal anti-inflammatory drugs are among the most widely prescribed drugs. In addition to gastrointestinal toxicity several renal complications are associated withtheir use, including acute renal failure, the nephrotic syndrome, interstitial nephritis, and abnormalities of water and electrolyte homoeostasis.1 Hyperkalaemia, usually associated with indomethacin, has only recently been recognised as a complication.'4 The objective of the present study was to determine prospectively the incidence and severity of hyperkalaemia in a population of npa tients receiving indomethacin.
Patients, methods, and results
We studied all 50 patients admitted to the department of medicine at this medical centre between October 1983 and July 1984 in whom treatment with indomethacin was started. The increase in serum potassium and blood urea nitrogen concentrations after treatment was defined as the difference between the highest measurement before and .fter indomethacin was started.
The increase in serum potassium concentration was less than 0 5 mmol (mEq)/l in 20 patients (group 1). An increase of 0-5-0-9 mmol/l was observed in 17 patients (group 2) and > 1-0 mmol/l in 13 patients (group 3). Absolute serum potassium concentrations exceeded 5 0 mmol/l in two (10%) patients in group 1 compared with eight (47%) patients in group 2 and all 13 patients in group 3. The mean (SD) daily dose of indomethacin was 168 (37) mg in group 1, 176 (22) mg in group 2, and 173 (35) mg in group 3.
The figure shows the variations in serum potassium concentrations in six patients in group 3 in whom peak values exceeded 6-0 mmol/l. In all patients potassium concentrations steadily increased until treatment with indomethacin was stopped. Peak values were observed on days 3-7 of treatment. Blood urea nitrogen concentration did not change or increased by less than 3-6 mmol/l (10 mg/100 ml) in 37 of the 50 patients. An increase of >3-6 mmol/l was found in four (20%) patients in group 1, two (12%) patients in group 2, and seven (54%) patients in group 3. These seven patients in group 3 had all had blood urea nitrogen concentrations before treatment exceeding 7.9 mmol/l (22 mg/100 ml).
The indications for treatment with indomethacin were musculoskeletal pain in 33 patients, pericarditis in 12, and fever associated with malignancy in three and autoimmune disease in two. The proportions of patients in these categories were the same for patients with and without a hyperkalaemic response to indomethacin. In contrast, the mean age of patients in group 1 (56-1 (18-8) years) was 10-12 years lower than that of patients in group 2 (66-9 (6-7)) and patients in group 3 (68-3 (11-9)) (p< 0-025). An impressive difference was the threefold (61 %) increase in the prevalence of mild to moderate (3-7-7-2 mmol/l (22-43 mg/100 ml)) pre-existent azotaemia in group 3 compared with groups 1 (25%) and 2 (18%) (p=0-01). 
Comment
We think that this study represents the first attempt to determine prospectively the incidence of hyperkalaemia in an inpatient population receiving indomethacin. Our findings indicate that hyperkalaemia is a common and potentially dangerous complication of treatment with indomethacin and that pre-existent mild to moderate azotaemia and old age are associated with an increased risk of the condition. Our findings together with previous reports lead us to make several recommendations for patients treated with indomethacin. Firstly, serum potassium concentrations should be measured in all patients before and repeatedly during the first week of treatment with indomethacin. Particular care should be exercised in patients with pre-existing renal disease, elderly subjects, and patients receiving potassium sparing diuretics, potassium supplements, angiotensin converting enzyme inhibitors, and 3 adrenergic blocking agents or digoxin. Finally, preexistent uraemia and hyperkalaemia should be regarded as contraindications to treatment with indomethacin.
In view of these considerations and reports indicating that some non-steroidal anti-inflammatory drugs such as sulindac do not interfere with renal synthesis of prostacyclin5 a prospective controlled trial comparing the incidence of hyperkalaemia, uraemia, and other renal complications in patients receiving therapeutic doses of indomethacin
